

## **Product Description**

Pioneering GTPase and Oncogene Product Development since 2010


## **SENP6 RABBIT PAB**

货号: S214089 产品全名: SENP6 兔多抗 基因符号 SSP1; SUSP1 UNIPROT ID: Q9GZR1 (Gene Accession - NP\_001093879) 背景: Ubiquitin-like molecules (UBLs), such as SUMOI (UBL1; MIM 601912), are structurally related to ubiquitin (MIM 191339) and can be ligated to target proteins in a similar manner as ubiquitin. However, covalent attachment of UBLs does not result in degradation of the modified proteins. SUMOI modification is implicated in the targeting of RANGAP1 (MIM 602362) to the nuclear pore complex as well as in stabilization of I-kappa-Balpha (NFKBIA; MIM 164008) from degradation by the 26S proteasome. 抗原: Synthetic peptide of human SENP6 经过测试的应用: ELISA, WB, IHC 推荐稀释比: IHC: 25-100;WB: 200-1000;ELISA: 5000-10000 种属反应性: Rabbit 克隆性: Rabbit Polyclonal 亚型: Immunogen-specific rabbit IgG 纯化: Antigen affinity purification 种属反应性: Human, Mouse 成分: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol 研究领域: Epigenetics and Nuclear Signaling, Cell Biology 储存和运输: Store at -20°C. Avoid repeated freezing and thawing





## **Product Description**

Pioneering GTPase and Oncogene Product Development since 2010




Immunohistochemistry analysis of paraffin embedded Human colorectal cancer tissue using 214089(SENP6 Antibody) at a dilution of 1/25(Nucleus).





The image on the left is immunohistochemistry of paraffinembedded Human tonsil tissue using 214089(Anti-SENP6 Antibody) at a dilution of 1/25.

In comparision with the IHC on the left, the same paraffin-embedded Human tonsil tissue is first treated with synthetic peptide and then with D161322(Anti-SENP6 Antibody) at dilution 1/25.



Gel: 6%SDS-PAGE, Lysate: 40 µg; Lane: Mouse brain tissue; Primary antibody: 214089(SENP6 Antibody) at dilution 1/200; Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution; Exposure time: 10 seconds



## **Product Description**

Pioneering GTPase and Oncogene Product Development since 2010